Preemption: The PMA "Shield"

Preemption: The PMA "Shield"

Discuss this with an attorney.

Medical device preemption refers to the legal principle that federal law can supersede or preempt state law in cases involving medical devices that have been approved by the Food and Drug Administration (FDA). This principle is rooted in the Medical Device Amendments (MDA) of 1976 to the Federal Food, Drug, and Cosmetic Act (FDCA), which gave the FDA authority to regulate medical devices.

Medical device preemption is based on the idea that once the FDA has reviewed and approved a medical device, states cannot impose additional requirements or regulations that differ from or add to federal standards. This ensures a consistent regulatory framework across the country and prevents a patchwork of state laws that could complicate compliance for device manufacturers.

Preemption has significant implications for litigation involving medical devices. If a device has gone through the FDA's premarket approval (PMA) process, manufacturers may be shielded from certain state law claims, such as those alleging design defects or failure to warn. Courts have often ruled that these claims are preempted because they would impose requirements different from or in addition to those approved by the FDA. A search in the FDA's MAUDE database may reveal thousands of allegations of injuries in PMA-approved products.

Not all claims are preempted. If a device manufacturer fails to comply with FDA regulations, they may still be liable under state law for negligence or breach of warranty.

Devices that have been cleared through the FDA's less rigorous 510(k) process may not be entitled to the same level of preemption protection as those that have undergone PMA.

Patients managing diabetes with medical devices choose between products cleared by 510(k) and products cleared by a new PMA or a supplement, from companies sheielded by preemption.

Facing severe cuts in the FDA's talented medical device review staff, perhaps now is the time to revise preemption, giving the state courts more power to resolve medical device injuries.



要查看或添加评论,请登录

James Causey的更多文章

  • Is AI on a Path to Insulin Pump Disruption?

    Is AI on a Path to Insulin Pump Disruption?

    Insulet's Omipod 5 leads by being tubeless, and disposable — but the user guide for the Beta Bionics iLet is less to…

    3 条评论
  • HbA1c? Time In Range?

    HbA1c? Time In Range?

    A haunting quote from Richard Feynman: "I think it's much more interesting to live not knowing than to have answers…

  • A Noninvasive Pitch? Target the Questions.

    A Noninvasive Pitch? Target the Questions.

    There may be a great path to a noninvasive glucose monitor that obviates inserting a wire-based electrochemical sensor,…

  • Medical Device Patient Support

    Medical Device Patient Support

    This is overhead on a balance sheet. It is urgent help to Type 1 patients when glucose changes at 1 mg/dL per minute…

    2 条评论
  • Integrated Continuous Glucose Monitors

    Integrated Continuous Glucose Monitors

    Sponsors of iCGMs report aggregated performance metrics spanning sensor sessions across a population of about 100 or…

  • Who Will Be Winning in 2030?

    Who Will Be Winning in 2030?

    The Omnipod 5 was not cleared as an ACE pump. The FDA found it to be substantially equivalent to the iAGC…

  • Sequel Med Tech, is Dose Resolution Enough?

    Sequel Med Tech, is Dose Resolution Enough?

    The Twiist pump may offer unprecedented occlusion sensitivity and accuracy at low dose rates—is that enough to compete?…

  • Physicians, Scientists, and Engineers Extend Lives

    Physicians, Scientists, and Engineers Extend Lives

    Managing Type 1 diabetes is not an acute intervention. Kudos to all who dedicate their careers to extending the…

    3 条评论
  • Experts Share Inside Perspectives

    Experts Share Inside Perspectives

    The insulin pump market is projected to reach $9B by 2030. The introduction of hybrid closed loop systems, enabled by…

  • Inhaled Insulin, Phone-based Glucose Controller, and AI-augmented Decision Support System

    Inhaled Insulin, Phone-based Glucose Controller, and AI-augmented Decision Support System

    Problem to Solve Maximize glucose time-in-range leveraging the most advanced technologies. Advanced Technologies…

社区洞察

其他会员也浏览了